1. Home
  2. NIE vs RLMD Comparison

NIE vs RLMD Comparison

Compare NIE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$26.47

Market Cap

745.4M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.59

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIE
RLMD
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
745.4M
661.9M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
NIE
RLMD
Price
$26.47
$6.59
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
76.8K
1.1M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
9.04%
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$22.78
$0.52
52 Week High
$27.24
$8.00

Technical Indicators

Market Signals
Indicator
NIE
RLMD
Relative Strength Index (RSI) 42.58 50.87
Support Level $25.99 $5.66
Resistance Level $27.13 $7.46
Average True Range (ATR) 0.47 0.42
MACD -0.12 0.04
Stochastic Oscillator 4.25 73.65

Price Performance

Historical Comparison
NIE
RLMD

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: